On December 1, 2009
Sanofi’s Cancer Division Next on the Chopping Block? Up to 1,200 Jobs Gone This Week
The cancer shoe has yet to drop at Sanofi-Aventis (SNY), a source tells BNET, as the company lays off as many as 1,200 sales reps and other staff. Sales of Sanofi’s Eloxatin cancer drug were decimated by generic competition this year, and the company is getting ready to ax many staff there.
0 Comments